Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Hemming-Harlo

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Vaccine|May 31, 2022
Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018)Maria Hemming-Harlo, Annette Gylling, Fredrik Herse, et al.
Journal of the Pediatric Infectious Diseases Society|October 21, 2016
Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in FinlandMaria Hemming-Harlo, Timo Vesikari, Matti Uhari, et al.
Vaccine|January 18, 2022
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)Jakub K Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Vaccine|May 31, 2022
Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018)Maria Hemming-Harlo, Annette Gylling, Fredrik Herse, et al.
Journal of the Pediatric Infectious Diseases Society|October 21, 2016
Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in FinlandMaria Hemming-Harlo, Timo Vesikari, Matti Uhari, et al.
Vaccine|January 18, 2022
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)Jakub K Simon, Nina Breinholt Staerke, Maria Hemming-Harlo, et al.
Pageof 2